To understand ophthalmologists' current perceptions and treatment of patients with moderate-to-severe dry eye disease (DED). Setting: Online survey. Methods: The online survey was sent to 7,882 ophthalmologists, including 51 corneal specialists, throughout the United States from October 9 to 21, 2008. The response rate was 3.1% (n ϭ 245), typical for this type of survey. Only ophthalmologists who treated four or more moderate-to-severe DED patients per month (235 of 245 [96%]) were asked to complete the survey. Results: Ninety-four percent of respondents agreed that more treatment options are needed for moderate-to-severe DED. Corneal specialists were more likely to strongly agree (63%) than general ophthalmologists (54%). Only 33% overall felt that current therapies were extremely or very effective for moderate DED and only 5% for severe disease. Ninety-two percent agreed that multiple therapeutic agents are needed to manage moderate-to-severe DED. The respondents prescribed or recommended a mean of 3.2 different treatments (standard deviation ϭ 1.2) for moderate DED patients over the course of a year and 4.9 (standard deviation ϭ 2.2) for patients with severe DED. The most highly ranked goals for treatment of moderate-to-severe DED patients were maintaining and protecting the ocular surface (ranked 1 or 2 ϫ 74%) and lubricating and hydrating the ocular surface (ranked 1 or 2 ϫ 67%). Corneal specialists ranked maintaining and protecting the ocular surface even more highly (ranked 1 or 2 ϫ 82%).
D
ry eye disease (DED), a multifactorial disease of the tears and ocular surface, is characterized by symptoms of discomfort, including burning, itching, foreign body sensation, soreness, dryness, photophobia, redness, and reduced visual acuity. [1] [2] [3] [4] The tear film instability of DED, which is accompanied by increased osmolarity of the tear film, is associated with inflammation and structural damage to the ocular surface. 1 Dry eye disease is a common clinical problem-approximately one in three patients seeking treatment from an ophthalmologist have symptoms of DED. 2 Approximately 5 million Americans aged 50 years and older have DED, with nearly twice as many women affected as men. 3 The number of individuals with DED is expected to increase dramatically as the population of older individuals rises in the coming decades. 3 Dry eye disease has significant impact on patients' activities of daily living and quality of life. Many patients with DED experience difficulty when reading, watching television, and using a computer. 2 In addition to the impact on patients' lives in both tangible symptoms and intangible decreases in leisure time, impaired physical functioning and quality of life, impact on social interactions, and mental and general health, DED directly impacts costs of care because of health care system use and indirectly contributes to lost work time and productivity. 3 A major stumbling block in the management of DED has been the lack of correlation between patients' symptoms and the results of clinical tests. 3 There is no single repeatable, reliable test in common use. 3 This discrepancy can be explained, in part, by the natural variability of the disease process, the subjective nature of DED symptoms, and variability of responses to questions about the physical sensations in the eyes and observer bias in recording slitlamp findings. 3 Compounding the challenge of diagnosis and treatment, some patients may present with severe damage to the ocular surface with no or few symptoms of DED. 2 A panel of questions was presented to practicing ophthalmologists throughout the United States to determine their perceptions of moderate-to-severe DED. In particular, the survey assessed how DED is treated and sought to identify areas of unmet therapeutic need for this disease.
METHODS
Survey questions (see Appendix) assessing participant demographics, perceptions of moderate-to-severe DED, DED treatment goals, DED therapeutic characteristics, measures of therapeutic success, and potential treatment gaps in DED were sent to 7,882 of the approximately 23,000 practicing ophthalmologists in the United States. Target ophthalmologists, who specialized in corneal/external eye disease, were identified by combining a pool of prespecified e-mail addresses with list of subscribers to Ophthalmology Times. Because the Ophthalmology Times subscription list represents the most of practicing ophthalmologists in the U.S., this was considered the best sample that was commercially available.
Prospective participants were sent an e-mail with a Web link to the online survey. To encourage participation in the survey, respondents were enrolled in a drawing to win a single prize of moderate value. No product was mentioned in the invitation or in the survey. (See Appendix for copy of e-mail invitation and online questionnaire.) Responses were collected from October 9 to 21, 2008, and were summarized in frequency tables organized by query.
To limit the survey to only those physicians who saw moderateto-severe dry eye patients on a regular basis, ophthalmologists who treated less than four cases of moderate-to-severe DED per month were not included. Four patients per month was considered the minimum that would qualify respondents to discuss treatment of these patients. An initial question, "How many moderate-to-severe dry eye patients do you treat per month?" was used to screen respondents. Only those who answered that they treat four or more moderate-to-severe dry eye patients per month were asked to complete the survey; this eliminated only 10 respondents (4.1%).
An additional and independent question was asked to the respondents who completed the entire survey, "How mild, moderate and/or severe dry eye patients do you see each week?" to determine how many dry eye patients in total the respondents typically see.
This survey was designed to profile the perceptions of ophthalmologists regarding the treatment of DED. All survey results are presented with descriptive statistics only, including mean and standard deviation (SD) where appropriate. No comparative analyses were anticipated or used in this survey. Percentages reported have a margin of error of Ϯ6.2% based on the 95% confidence limits of a survey of this size. For example, a survey finding of 50% has a 95% confidence interval of 43.8% to 56.2%. The study was submitted to Mt Sinai's institutional review board, and an institutional review board waiver was provided.
Data obtained from surveys of this type have limitations that should be acknowledged. Respondents were limited to those ophthalmologists who could be reached online, and the percentage of respondents was, as is typical of such surveys, relatively small (3.1%), and thus, may not be entirely representative of the overall population. Telephone surveys, which include multiple follow-up calls, can obtain response rates as high as 30%. Ophthalmology Times reports that results of its online surveys have ranged from as low as 1.4% to as high as 6.4%, with a mean response rate of 3% [Michael Shaffer, personal communication (Ophthalmology Times)]. It should be noted, however, that the geographic distribution of the respondent cohort in the United States was similar to that reported by the American Medical Association (AMA) for ophthalmologists as a group (Table 1) . 4 Similarly, the sex distribution of the respondents (78% men, 22% women) was close to that reported by the AMA (80.7% men, 19.3% women) for the overall ophthalmology community. 5 Another potential source of error is skewing of the survey results by the inclusion of respondents outside the United States where available treatments may differ from those available in the U.S. Only 10 respondents (4%; all in Canada) fell into this category. However, such small numbers were unlikely to have produced a significant bias.
RESULTS

Respondent Demographics
Of 7,882 targeted ophthalmologists, 245 (3.1%) responded to the invitation to complete the survey. Of the participants, most (73.9%; n ϭ 181) were men, 21.2% (n ϭ 52) were women, and 4.9% (n ϭ 12) did not specify their sex. Respondents represented all regions of the United States, including the Northeast (25.3%; n ϭ 62), the Southwest (22.0%; n ϭ 54), the Southeast (20.0%; n ϭ 49), the Midwest (19.6%; n ϭ 48), the Northwest (2.0%; n ϭ 5), and other regions of the United States including Puerto Rico (1.6%; n ϭ 4). Ten respondents (4.1%) were from outside the United States, and 13 (5.3%) did not specify their location. Overall, the U.S. distribution of ophthalmologists participating in the survey was similar to the distribution reported by the AMA 5 (Table 1) .
Respondents had spent an average of 17.4 years in practice. Most of the participants (66.1%; n ϭ 154) had been in practice for more than 10 years. Most respondents indicated that they were comprehensive ophthalmologists (66.2%; n ϭ 153), and 22.1% (n ϭ 51) stated that they were corneal specialists. Twenty-seven respondents (11.7%) indicated that they were involved in another specialty, whereas 5.7% (n ϭ 14) did not provide a response to this query. On average, participants reported that they see 112.4 patients per week-of these, approximately 1 in 5 (n ϭ 23.1) are patients with mild, moderate, or severe DED. Respondents who treat less than four moderate-to-severe DED patients per month (n ϭ 10; 4.1% of total respondents) were not included in the analysis of subsequent responses.
Perceived Causation of DED
Respondents were asked to indicate by percentage range the primary cause of DED among their patients with moderate-tosevere disease. Participants could select more than one category as a primary cause-results presented are not cumulative. Listed primary causes included Sjogren's syndrome or other autoimmune disease, environmental conditions, postmenopausal hormonal changes, laser in situ keratomileusis (LASIK) or other ocular surgery, contact lens use, use of systemic medications, or eye/ eyelid injury or conditions. Participants were permitted to write in other primary cause of DED if it was not included in the list provided. Respondents indicated that environmental factors and postmenopausal hormonal changes are the most common primary causes of moderate-to-severe DED in their patients, affecting an average of 36.2% and 34.3%, respectively (Fig. 1) . Participants indicated that, in decreasing order of average frequency, use of systemic medications (21.3%), contact lens use (20.7%), eye/ eyelid injury or conditions (19.7%), Sjogren's syndrome or other autoimmune disease (18.9%), and LASIK or other ocular surgery (17.3%) were also related to DED in their patients. a Other included respondents from other U.S. regions (e.g., Puerto Rico) and from outside the U.S.
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Survey participants were also asked to indicate if they believed inflammation is the underlying cause of DED, or whether it is merely a consequence of the disease. Most respondents (68.6%; n ϭ 168) indicated that inflammation is the underlying cause of DED, whereas 26.1% (n ϭ 64) felt inflammation is a consequence of the disease. Thirteen participants (5.3%) did not provide an answer to this question.
Treatment Goals and Therapy for Moderate-toSevere DED
Participants were asked to rank, in order of overall importance, the goals of treatment of moderate-to-severe DED. On a scale from 1 (most important) to 6 (least important), respondents could rank among the following options: prolonging tear film breakup time, stimulating tear production, lubricating and hydrating the ocular surface, inhibiting inflammatory factors, helping patients tolerate contact lenses, and maintaining and protecting the ocular surface. As shown in Figure 2 , survey participants indicated that the most important goal of DED treatment is maintenance and protection of the ocular surface (mean score 1.0, SD ϭ 1.4), followed closely by lubrication and hydration of the ocular surface (mean score 1.4, SD ϭ 1.3).
Survey respondents were asked to rank determinants of successful treatment of moderate-to-severe DED on a scale of 1 (most important) to 7 (least important). Criteria for measuring successful treatment included lengthening of tear film breakup time, decrease in Rose Bengal, fluorescein, or lissamine green staining, increase of Schirmer's test score, improved vision, or relief of symptoms/ patient satisfaction, increase in tear film meniscus, and prevention of damage to the cornea. As shown in Figure 3 , participants indicated that relief of symptoms/patient satisfaction (mean score 1.0, SD ϭ 1.0) was the most important determinant of successful treatment of moderate-to-severe DED, followed by prevention of damage to the cornea (mean score 2.5, SD ϭ 1.5).
The survey also asked participants to estimate how many different treatment approaches they prescribe or recommend for mild, moderate, and severe DED over the course of 1 year. Respondents prescribe or recommend an average of 1.9 treatment approaches for mild DED, 3.2 approaches for moderate DED, and 4.9 approaches for severe DED. 23.4% of the participants were using four or more approaches to treat moderate dry eye, while 72.1% were using four or more approaches to treat severe dry eye (Table 2) .
Participants were also asked to select that which qualities of treatment options for DED they take into consideration when developing a treatment plan for a patient with moderate-to-severe DED. Respondents could select from a list including preservative free, dosing frequency, length of time preserving the tear film, length of time to effectiveness, patient acceptance, ability to use with contact lenses, ability to provide continuous relief, ability for concomitant use with other medications, and ability to use longterm. The treatment characteristics that participants most frequently selected as key considerations (summarized in Table 3) were the ability to provide continuous relief (84.2% of participants selected this answer) and patient acceptance (82.5% of participants chose this response).
Areas of Concern When Treating Moderate-toSevere DED
The survey asked respondents to indicate how effective they believe current therapies for mild, moderate, and severe DED ; n ϭ 187) indicated that current treatments for mild DED are extremely or very effective, while 32.5% (n ϭ 76) also ranked therapies for moderate DED in this category. Twelve (5.1%) of respondents indicated that current treatments for severe DED are extremely or very effective, whereas 38.2% (n ϭ 89) felt therapies for severe DED are not very or not at all effective. Participants were also asked to provide their opinion of a set of presented statements, including the following: whether more treatment options are needed for moderate-to-severe DED; treatment of DED can help establish a practice; DED is difficult to diagnose; the signs and symptoms of moderate-to-severe DED are can be improved but seldom eliminated; there is a treatment gap between artificial tears and more aggressive treatments for moderate-tosevere DED; and multiple therapeutic agents are usually needed to manage moderate-to-severe DED. As summarized in Table 4 , most of the respondents agreed that more treatment options are needed for moderate-to-severe DED (94.4%; n ϭ 219). Corneal specialists were more likely to strongly agree (63%) than general ophthalmologists (54%). Participants also agreed that multiple therapeutic agents are usually necessary to manage moderate-to-severe disease (92.3%; n ϭ 215), that a gap exists between treatment with artificial tears and more aggressive therapy for moderate-to-severe DED (82.7%; n ϭ 191), and that while signs and symptoms may improve, they are seldom eliminated (81.1%; n ϭ 189). Most participants (80.6%; n ϭ 187) disagreed with the statement that DED is difficult to diagnose.
General Ophthalmologists versus Corneal Specialists
Although the sample size was not large enough to detect statistically significant differences between general ophthalmologists and corneal specialists-nor was the survey intended tosome difference in trends were observed. A total of 82% of the corneal specialists ranked "maintaining and protecting the ocular surface" as first or second goal of treatment, compared with 73% of the comprehensive/general ophthalmologists. Sixty-three percent (63%) of the corneal specialists strongly agreed that more treatment options are needed for moderate/severe dry eye, compared with 54% of comprehensive/general ophthalmologists. A total of 49% of the corneal specialists strongly agreed that multiple therapeutic agents are usually needed to manage moderate/severe dry eye, compared with 40% of comprehensive/general ophthalmologists.
DISCUSSION
The results of this survey provide insight into the current perceptions of moderate-to-severe DED and its treatment held by comprehensive ophthalmologists and corneal specialists throughout the United States. Only 10 of the 245 participants who responded to the invitation to complete the survey (4.1%) indicated that they see less than 4 moderate-to-severe DED patients per month, emphasizing the common clinical presentation of the disease. Consistent with the accepted cause of DED, respondents confirmed that the disease is indeed multifactorial in nature. 3 Although environmental conditions of low humidity and postmenopausal hormonal changes were indicated as leading primary causes of DED, systemic medications, use of contact lenses, eye/eyelid injury, Sjogren's disease, and LASIK or other ocular surgery were identified as major primary causes with approximately equal frequency.
Respondents indicated that successful management of the disease is often measured by patient-reported improvement in symptoms and overall satisfaction. It is of particular interest that although most participants in this survey identify inflammation as an underlying cause of DED, they identify protection of the ocular surface and lubrication of the eye as the most important goals of treatment. However, this does not obviate the need for treatment to address the underlying pathogenetic causes of dry eye as well, including inflammation and the basis of the inflammation.
The inflammation of the ocular surface observed in DED, regardless of whether it is an underlying cause or an effect of the disease, is exacerbated by preservatives found in most dry eye therapies. 6 Preservatives such as benzalkonium chloride may cause damage to the corneal and conjunctival epithelium. 7 As noted in the Dry Eye WorkShop report, effective, preservative-free treat- The question asked was "When selecting products for moderate to severe dry eye patients, which of the following are key considerations?" (Multiple responses allowed). The question asked was "Please indicate your level of agreement with the following statements."
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Eye & Contact Lens • Volume 36, Number 1, January 2010 ment options may be important, particularly for patients who suffer from moderate-to-severe DED. 6 The difficulty of treating severe DED is indicated by the survey respondents' report of prescribing or recommending an average of nearly five treatments over the course of a year with these patients. This likely reflects the use for multiple, concomitant treatment approaches and the need for trial of various treatments with the severe patients.
As expected, respondents indicated that they prescribe or recommend more treatment options for increasingly advanced DED. Most participants stated that current treatment options for patients with severe DED are not effective and that a gap exists between currently available artificial tears and effective therapy. Participants identified a clear need for additional options that provide continuous relief of DED symptoms and that are acceptable to patients. A preservative-free therapeutic option that provides continuous, long-term relief of DED symptoms would be highly desirable.
Although the results of this survey provide insight into ophthalmologists' current perceptions and treatment of patients with moderate-to-severe DED, it does not address patients' perceptions of the disease. A future survey to compare patients' responses may provide additional insight because of the general lack of correlation between the signs and symptoms of DED.
